The National Drug Code (NDC) for Wegovy 1 mg is 00169-0210-10 [1]. Wegovy is a brand-name prescription medication used for chronic weight management [2]. It contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist [2].
How is Wegovy 1 mg administered?
Wegovy 1 mg is administered as a subcutaneous injection once weekly [2]. It is available in a pre-filled pen designed for self-administration [2].
What is the dosage strength of Wegovy 1 mg?
The 1 mg strength is one of several available dosage strengths for Wegovy, which also include 0.25 mg, 0.5 mg, 1.7 mg, and 2.4 mg [2]. The dosage is typically increased gradually by a healthcare provider to reach the target maintenance dose [2].
What is semaglutide and how does it work?
Semaglutide is a GLP-1 receptor agonist that mimics the action of the natural incretin hormone GLP-1 [2]. It helps regulate blood sugar by increasing insulin secretion and decreasing glucagon secretion [2]. In the context of weight management, it slows gastric emptying and reduces appetite, leading to decreased food intake and weight loss [2].
When does Wegovy's patent expire?
Patent expiry dates for medications can be complex due to multiple patents covering different aspects of the drug, such as formulation, manufacturing, and method of use. Information on specific patent expiry dates for Wegovy can be found on resources like DrugPatentWatch.com [3]. For semaglutide, various patents are listed, with some expiring in the mid-to-late 2030s [3].
Are there generic versions of Wegovy available?
As of late 2023, generic versions of Wegovy (semaglutide) are not yet available in the United States [4]. Generic competition typically emerges after the expiration of relevant patents and any associated market exclusivity periods.
What are the potential side effects of Wegovy?
Common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, and indigestion [2]. More serious, though less common, side effects can include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and a risk of thyroid tumors [2]. Patients should discuss potential risks with their healthcare provider.
How does Wegovy compare to other weight loss medications?
Wegovy (semaglutide) is in the same class of drugs as liraglutide (Saxenda) and tirzepatide (Mounjaro, Zepbound), all of which are GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists and are used for chronic weight management [5]. These medications differ in their specific mechanisms of action, efficacy, side effect profiles, and approved indications [5].
What clinical data supports Wegovy's use for weight management?
Wegovy's approval for chronic weight management is based on clinical trial data demonstrating significant weight loss in adults and adolescents with obesity or overweight and at least one weight-related comorbidity [2]. The STEP trials are key studies evaluating semaglutide for weight management [2].
What are the regulatory approvals for Wegovy?
Wegovy is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults and adolescents aged 12 and older who have obesity or are overweight and have at least one weight-related condition [2].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/wegovy
[2] https://www.wegovy.com/
[3] https://www.drugpatentwatch.com/semaglutide
[4] https://www.goodrx.com/wegovy/generics
[5] https://www.niddk.nih.gov/health-information/weight-management/adult-weight-loss-medications